Five Prime Therapeutics, Inc. (FPRX) Receives $59.17 Average PT from Brokerages

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has been given an average rating of “Buy” by the eleven research firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $58.00.

FPRX has been the subject of a number of recent analyst reports. Royal Bank Of Canada initiated coverage on shares of Five Prime Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $41.00 price target for the company. BMO Capital Markets upgraded shares of Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, October 16th. BidaskClub cut shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Jefferies Group LLC restated a “buy” rating and set a $52.00 price target (down from $55.00) on shares of Five Prime Therapeutics in a report on Thursday, August 10th.

Shares of Five Prime Therapeutics (NASDAQ:FPRX) traded up 0.76% during mid-day trading on Wednesday, hitting $46.29. The stock had a trading volume of 344,159 shares. Five Prime Therapeutics has a one year low of $25.97 and a one year high of $60.98. The firm’s 50 day moving average price is $39.82 and its 200-day moving average price is $32.82. The company’s market cap is $1.30 billion.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The firm had revenue of $7.80 million for the quarter, compared to the consensus estimate of $8.32 million. During the same quarter last year, the company earned ($0.49) earnings per share. The firm’s revenue was down 16.1% on a year-over-year basis. On average, equities research analysts anticipate that Five Prime Therapeutics will post ($5.29) earnings per share for the current fiscal year.

In related news, Director William R. Ringo sold 2,000 shares of the stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $38.00, for a total value of $76,000.00. Following the completion of the transaction, the director now owns 2,000 shares of the company’s stock, valued at $76,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William R. Ringo sold 1,800 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $40.26, for a total transaction of $72,468.00. Following the completion of the transaction, the director now directly owns 1,200 shares of the company’s stock, valued at approximately $48,312. The disclosure for this sale can be found here. 6.50% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Creative Planning raised its position in Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 54 shares in the last quarter. Legal & General Group Plc raised its position in Five Prime Therapeutics by 3.1% in the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 287 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Five Prime Therapeutics by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,449 shares of the biotechnology company’s stock worth $646,000 after purchasing an additional 397 shares in the last quarter. Rhumbline Advisers raised its position in Five Prime Therapeutics by 1.4% in the second quarter. Rhumbline Advisers now owns 34,282 shares of the biotechnology company’s stock worth $1,032,000 after purchasing an additional 484 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. raised its position in Five Prime Therapeutics by 3.0% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,227 shares of the biotechnology company’s stock worth $518,000 after purchasing an additional 494 shares in the last quarter. 84.01% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/10/30/five-prime-therapeutics-inc-fprx-receives-59-17-average-pt-from-brokerages.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

What are top analysts saying about Five Prime Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Five Prime Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit